DRKS00013025招募中不适用
Platelet inhibition to reduce formation of non-alcohol steatohepatitis in cardiovascular patients - PROMETHEUS
niversitätsklinikum Tübingen0 个研究点目标入组 150 人开始时间: 2018年2月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with an age from 18-80 years with symptomatic cardiovascular disease and a high-risk profile including diabetes mellitus type II and/or obesity with BMI =30
排除标准
- •History of viral hepatitis
- •Patients with alcoholic steatohepatitis (ASH)
研究者
相似试验
进行中（未招募）
不适用
Effect of three different ticagrelor loading dose formulations (crushed, chewed or intact tablets) on the degree and rapidity of platelets ability to clump together and form clots in patients with stable angina referred for coronary angiographyEUCTR2014-002227-96-SECounty Council of Östergötland
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGESubjects who present with an acute coronary syndrome.MedDRA version: 12.0Level: LLTClassification code 10051592Term: Acute coronary syndromeMedDRA version: 12.0Level: PTClassification code 10051592Term: Acute coronary syndromeMedDRA version: 12.0Level: LLTClassification code 10006894Term: CABGEUCTR2008-001135-35-CZThe Medicines Company220
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGEEUCTR2008-001135-35-GBThe Medicines Company220
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGEEUCTR2008-001135-35-NLThe Medicines Company220
已完成
2 期
Maintenance of platelet inhiBition with cangreloR after dIscontinuation of thienopyriDines in patients undergoing surGEry: The BRIDGE trialplatelet inhibition10011082NL-OMON34815Medicines Company50